Zeitschriftenartikel zum Thema „Multiple myeloma Chemotherapy“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Multiple myeloma Chemotherapy" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Durie, Brian G. M. „Chemotherapy of multiple myeloma“. Baillière's Clinical Haematology 4, Nr. 1 (Januar 1991): 181–95. http://dx.doi.org/10.1016/s0950-3536(05)80290-2.
Kogan, Michael, und Adnan H. Siddiqui. „Intracranial Multiple Myeloma After Chemotherapy“. Archives of Clinical and Medical Case Reports 01, Nr. 02 (2017): 42–44. http://dx.doi.org/10.26502/acmcr.9655008.
Lokhorst, H. M., O. J. A. Th Meuwissen, E. J. E. G. Bast und A. W. Dekker. „VAD chemotherapy for refractory multiple myeloma“. British Journal of Haematology 71, Nr. 1 (Januar 1989): 25–30. http://dx.doi.org/10.1111/j.1365-2141.1989.tb06269.x.
Peest, D., H. J. Schmoll, I. Schedel, S. Glück, K. Schumacher und H. Deicher. „VBAMDex chemotherapy in advanced multiple myeloma*“. European Journal of Haematology 40, Nr. 3 (24.04.2009): 245–49. http://dx.doi.org/10.1111/j.1600-0609.1988.tb00831.x.
Terrovitis, John V., Charis Matsouka, Athanassios Anagnostopoulos, Maria I. Anastasiou-Nana und Athanassios Meletios Dimopoulos. „Hemophagocytic Lymphohistiocytosis After Chemotherapy for Multiple Myeloma“. Clinical Lymphoma 5, Nr. 3 (Dezember 2004): 194–96. http://dx.doi.org/10.3816/clm.2004.n.026.
Alexanian, Raymond, Bart Barlogie und Gerard Ventura. „Chemotherapy for resistant and relapsing multiple myeloma“. European Journal of Haematology 43, S51 (24.04.2009): 140–44. http://dx.doi.org/10.1111/j.1600-0609.1989.tb01507.x.
Vidarsson, Brynjar, Svanhvit Olafsdottir und Sigrun Reykdal. „VASP Chemotherapy in Patients with Multiple Myeloma.“ Blood 106, Nr. 11 (16.11.2005): 5189. http://dx.doi.org/10.1182/blood.v106.11.5189.5189.
Minařík, Jiří, und Sabina Ševčíková. „Immunomodulatory Agents for Multiple Myeloma“. Cancers 14, Nr. 23 (23.11.2022): 5759. http://dx.doi.org/10.3390/cancers14235759.
Katagiri, Daisuke, Eisei Noiri und Fumihiko Hinoshita. „Multiple Myeloma and Kidney Disease“. Scientific World Journal 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/487285.
Bensinger, William I. „Hematopoietic Cell Transplantation for Multiple Myeloma“. Cancer Control 5, Nr. 3 (Mai 1998): 235–42. http://dx.doi.org/10.1177/107327489800500304.
&NA;. „High-dose chemotherapy + stem cells for multiple myeloma“. Inpharma Weekly &NA;, Nr. 1387 (Mai 2003): 13. http://dx.doi.org/10.2165/00128413-200313870-00036.
Rohatgi, Nidhi, Xianglin L. Du, Ann L. Coker, Lemuel A. Moye, Michael Wang und Shenying Fang. „Chemotherapy and Survival for Patients With Multiple Myeloma“. American Journal of Clinical Oncology 30, Nr. 5 (Oktober 2007): 540–48. http://dx.doi.org/10.1097/coc.0b013e3180592a30.
Anderson, H., JH Scarffe, M. Ranson, R. Young, GS Wieringa, GR Morgenstern, L. Fitzsimmons und D. Ryder. „VAD chemotherapy as remission induction for multiple myeloma“. British Journal of Cancer 71, Nr. 2 (Februar 1995): 326–30. http://dx.doi.org/10.1038/bjc.1995.65.
Puri, Sonam, Jitesh Joshi, Olga Derman, Noah Kornblum, Amit Verma, Ira Braunschweig und Ramakrishna Battini. „Ocular Complications of Bortezomib Therapy in Multiple Myeloma“. Blood 124, Nr. 21 (06.12.2014): 5743. http://dx.doi.org/10.1182/blood.v124.21.5743.5743.
Kristinsson, Sigurdur Yngvi. „Thrombosis in Multiple Myeloma“. Hematology 2010, Nr. 1 (04.12.2010): 437–44. http://dx.doi.org/10.1182/asheducation-2010.1.437.
Chng, Wee Joo, Lee Gong Lau, Noorainun Yusof und Benjamin M. F. Mow. „Targeted Therapy in Multiple Myeloma“. Cancer Control 12, Nr. 2 (April 2005): 91–104. http://dx.doi.org/10.1177/107327480501200204.
Lonial, Sagar. „Relapsed Multiple Myeloma“. Hematology 2010, Nr. 1 (04.12.2010): 303–9. http://dx.doi.org/10.1182/asheducation-2010.1.303.
Li, Juan, Junhe Li, Shaokai Luo und Yin Zhao. „Expression of TRAIL Receptors on the Multiple Myeloma Cells.“ Blood 104, Nr. 11 (16.11.2004): 4868. http://dx.doi.org/10.1182/blood.v104.11.4868.4868.
Luca, Dragos C., und Imad Y. Almanaseer. „Simultaneous Presentation of Multiple Myeloma and Acute Monocytic Leukemia“. Archives of Pathology & Laboratory Medicine 127, Nr. 11 (01.11.2003): 1506–8. http://dx.doi.org/10.5858/2003-127-1506-spomma.
Tu, Yong-sheng, Jin He, Huan Liu, Richard Eric Davis, Robert Z. Orlowski, Joshua E. Allen und Jing Yang. „ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma“. Blood 128, Nr. 22 (02.12.2016): 4476. http://dx.doi.org/10.1182/blood.v128.22.4476.4476.
Mohamed, Muhajir, und Karen Dun. „Complex hypodiploid acute myeloid leukaemia secondary to chemotherapy for hyperdiploid multiple myeloma“. International Journal of Hematology 100, Nr. 1 (13.05.2014): 3–6. http://dx.doi.org/10.1007/s12185-014-1594-y.
Huff, Carol Ann, und William Matsui. „Multiple Myeloma Cancer Stem Cells“. Journal of Clinical Oncology 26, Nr. 17 (10.06.2008): 2895–900. http://dx.doi.org/10.1200/jco.2007.15.8428.
Todaro, Juliana, Patrícia Weinschenker Bollmann, Amit Nussbacher, Luis Fernando Aranha Camargo, Bento Fortunato Cardoso dos Santos, Daniel Alvarenga, Laercio Alberto Rosemberg, David Costa de Souza Le Bihan, Cláudio Henrique Fischer und Auro del Giglio. „Multiple myeloma complicated with pseudomonas endocartiditis“. Einstein (São Paulo) 10, Nr. 4 (Dezember 2012): 498–501. http://dx.doi.org/10.1590/s1679-45082012000400017.
Chandran, Rekha, Miklos Simon und Stephen E. Spurgeon. „Concurrent Presentation of Hodgkin Lymphoma and Multiple Myeloma“. Case Reports in Hematology 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/398769.
Berneman, Zwi N., An-Sofie Verstraete, Alain Gadisseur, Ann Van de Velde und Wilfried A. Schroyens. „The Survival of Multiple Myeloma Patients: A Single Institution Study.“ Blood 104, Nr. 11 (16.11.2004): 5223. http://dx.doi.org/10.1182/blood.v104.11.5223.5223.
Kaneko, Haruo, Ken Shikoshi, Shuichi Annou, Masashi Takada, Motoharu Kato, Setsuro Moro, Mikio Yamauchi und Tatsuo Shirai. „VCAP Combination Chemotherapy for Multiple Myeloma in the Aged.“ Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 28, Nr. 4 (1991): 504–8. http://dx.doi.org/10.3143/geriatrics.28.504.
Johnstone, Megan, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson und Annamaria Gulla. „Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma“. Cells 11, Nr. 16 (14.08.2022): 2519. http://dx.doi.org/10.3390/cells11162519.
Ii, Frederick Richards, Morton Coleman, M. Robert Cooper und W. Perry Ballard. „Multiple Myeloma—Complete Remission with High Dose Melphalan Chemotherapy“. Cancer Investigation 3, Nr. 1 (Januar 1985): 15–21. http://dx.doi.org/10.3109/07357908509040604.
Wright, A., S. Elkins, J. Files, C. Bigelow, V. Herrin und M. Sample. „THROMBOEMBOLISM IN MULTIPLE MYELOMA PATIENTS RECEIVING THALIDOMIDE COMBINATION CHEMOTHERAPY.“ Journal of Investigative Medicine 55, Nr. 1 (Januar 2007): S302. http://dx.doi.org/10.1097/00042871-200701010-00839.
Ucci, G., A. Riccardi, P. Dörmer, M. Danova und R. Luoni. „Early Plasma Cell Recruitment In Multiple Myeloma Following Chemotherapy“. Cell Proliferation 21, Nr. 6 (November 1988): 405–9. http://dx.doi.org/10.1111/j.1365-2184.1988.tb00800.x.
Palva, I. P., P. Ahrenberg, A. Almquist, K. Ala-Harja, J. Apajalahti, H. Hallman, A. Hänninen et al. „Aggressive combination chemotherapy in multiple myeloma. A multicentre trial“. Scandinavian Journal of Haematology 35, Nr. 2 (24.04.2009): 205–9. http://dx.doi.org/10.1111/j.1600-0609.1985.tb01574.x.
Palva, I. P. „Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma“. European Journal of Haematology 48, Nr. 1 (24.04.2009): 37–40. http://dx.doi.org/10.1111/j.1600-0609.1992.tb01791.x.
Fassas, Athanasios B. T., Trey Spencer, Raman Desikan, Maurizio Zangari, Elias Anaissie, Bart Barlogie und Guido Tricot. „Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients“. British Journal of Haematology 119, Nr. 1 (Oktober 2002): 164–68. http://dx.doi.org/10.1046/j.1365-2141.2002.03772.x.
SWAN, GEORGE W. „Optimal Control Applications in the Chemotherapy of Multiple Myeloma“. Mathematical Medicine and Biology 2, Nr. 3 (1985): 139–60. http://dx.doi.org/10.1093/imammb/2.3.139.
Zhan, Fenghuang, Wen Zhou, Maurizio Zangari, Hongwei Xu und Guido J. Tricot. „ALDH1 Activity Identifies Chemotherapy-Resistant Multiple Myeloma Stem Cells“. Blood 118, Nr. 21 (18.11.2011): 990. http://dx.doi.org/10.1182/blood.v118.21.990.990.
Becker, Pamela S. „Genetic Predisposition for Chemotherapy-Induced Neuropathy in Multiple Myeloma“. Journal of Clinical Oncology 29, Nr. 7 (01.03.2011): 783–86. http://dx.doi.org/10.1200/jco.2010.33.4771.
Song, Yan, Ning Hu, Xiaowei Song und Juhong Yang. „Hsa_Circ_0007841 Enhances Multiple Myeloma Chemotherapy Resistance Through Upregulating ABCG2“. Technology in Cancer Research & Treatment 19 (01.01.2020): 153303382092837. http://dx.doi.org/10.1177/1533033820928371.
Kryukov, E. V., V. N. Troyan, O. A. Rukavitsyn, S. V. Kozyrev, I. G. Daragan-Sushchov, V. P. Pop, S. A. Alekseev und E. R. Sapelnikova. „Densitometry as a monitoring method in the treatment of patients with multiple myeloma“. Medical Visualization, Nr. 5 (28.10.2018): 106–13. http://dx.doi.org/10.24835/1607-0763-2018-5-106-113.
Sinclair, David, Adel Resouly und Anne Spedding. „Stridor: unusual presentation of multiple myeloma“. Journal of Laryngology & Otology 117, Nr. 10 (Oktober 2003): 829–31. http://dx.doi.org/10.1258/002221503770716313.
Israelyan, E. R., C. S. Golovataya, O. K. Bondarenko, A. V. Nayda und A. K. Pudeeva. „Onset of multiple myeloma with rheumatic polymyalgia“. Medical Herald of the South of Russia 10, Nr. 4 (26.12.2019): 98–104. http://dx.doi.org/10.21886/2219-8075-2019-10-4-98-104.
Palva, I. P., K. Ala-Harja, A. Almqvist, E. Elonen, H. Hallman, A. Hänninen, M. Ilvonen et al. „Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma“. European Journal of Haematology 51, Nr. 2 (24.04.2009): 98–101. http://dx.doi.org/10.1111/j.1600-0609.1993.tb01600.x.
Salmon, S. E., J. J. Crowley, T. M. Grogan, P. Finley, R. P. Pugh und B. Barlogie. „Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.“ Journal of Clinical Oncology 12, Nr. 11 (November 1994): 2405–14. http://dx.doi.org/10.1200/jco.1994.12.11.2405.
Coss, Alan, Chen Zhou, Michael F. Byrne und Alan A. Weiss. „Relapse of Multiple Myeloma Presenting with Biliary Obstruction“. Canadian Journal of Gastroenterology 24, Nr. 4 (2010): 237–38. http://dx.doi.org/10.1155/2010/593859.
Sawicki, C. P., S. A. Climans, C. C. Hsia und J. A. Fraser. „Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy“. Current Oncology 25, Nr. 1 (28.02.2018): 99. http://dx.doi.org/10.3747/co.25.3674.
Haegelen, Claire, Laurent Riffaud, Marc Bernard, Beatrice Carsin-Nicol und Xavier Morandi. „Dural plasmacytoma revealing multiple myeloma“. Journal of Neurosurgery 104, Nr. 4 (April 2006): 608–10. http://dx.doi.org/10.3171/jns.2006.104.4.608.
Sampat, Parth J., Maneesh Bisen, Nimisha Srivastava, Suman Rao und Teresa Gentile. „Accidental Ixazomib Overdose in a Patient With Multiple Myeloma“. Journal of Investigative Medicine High Impact Case Reports 9 (Januar 2021): 232470962110132. http://dx.doi.org/10.1177/23247096211013230.
Rathnakumar, Geeta, Kinjalka Ghosh, Nikhil Choudhary, Narendra Kamble und Nitin Inamdar. „Study of prognostic factors in multiple myeloma“. International Journal of Advances in Medicine 8, Nr. 11 (26.10.2021): 1694. http://dx.doi.org/10.18203/2349-3933.ijam20214131.
Quesada, JR, R. Alexanian, M. Hawkins, B. Barlogie, E. Borden, L. Itri und JU Gutterman. „Treatment of multiple myeloma with recombinant alpha-interferon“. Blood 67, Nr. 2 (01.02.1986): 275–78. http://dx.doi.org/10.1182/blood.v67.2.275.275.
Quesada, JR, R. Alexanian, M. Hawkins, B. Barlogie, E. Borden, L. Itri und JU Gutterman. „Treatment of multiple myeloma with recombinant alpha-interferon“. Blood 67, Nr. 2 (01.02.1986): 275–78. http://dx.doi.org/10.1182/blood.v67.2.275.bloodjournal672275.
Ostrovskyi, V. L., I. M. Skrypnyk, G. S. Maslova, O. A. Shaposhnyk und L. I. Yakymyshyna. „PECULIARITIES OF MYOCARDIAL BIOELECTRIC ACTIVITY IN PATIENTS WITH PROGRESSIVE MYLTIPLE MYELOMA RECEIVING BORTEZOMIB-CONTAINING CHEMOTHERAPY SCHEMES“. Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 22, Nr. 3-4 (29.11.2022): 80–84. http://dx.doi.org/10.31718/2077-1096.22.3.4.80.